(Abst.) Advances in oral immunomodulating therapies in relapsing MS on: February 17, 2020, 08:41:13 pm #1 From PubMed, indexing an article in The Lancet, "Advances in oral immunomodulating therapies in relapsing multiple sclerosis" (February 11, 2020): Advances in oral immunomodulating therapies in relapsing multiple sclerosis - PubMed New sphingosine-1-phosphate receptor (S1PR) modulators with more specific S1PR target profiles and potentially better safety profiles compared with fingolimod were tested in patients with relapsing... PubMed · ncbi.nlm.nih.gov Logged MS Speaks--online for 20 yearsSPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) 12/16/20 - 3/16/24.
